PeptideCompareSurvodutide — EU research guide.
Survodutide (BI 456906) is a dual GLP-1 receptor and glucagon receptor agonist developed by Boehringer Ingelheim / Zealand Pharma, studied for obesity and MASH (metabolic-associated steatohepatitis).
What is Survodutide?
Survodutide activates both GLP-1R (promoting satiety and insulin secretion) and GCGR (increasing energy expenditure and hepatic fat metabolism). The glucagon component distinguishes it from semaglutide and gives it a stronger liver-directed metabolic effect, making it of particular interest in MASH research.
What does the research show?
Phase 2 results showed ~19% body weight reduction at 46 weeks. In MASH patients, significant liver fat reduction and histological improvement were observed. Phase 3 trials are ongoing. The GCGR activation carries theoretical risk of hyperglycaemia in non-obese subjects — an active research area.
EU legal status
Not EMA or FDA approved. Investigational compound available for laboratory research purposes only.
Molecular information
Pharmacokinetics
Potency retained over time
Each line is one storage condition: it starts at 100% and declines as potency is lost. Above the dotted 80% line the material is considered reliable — hover the chart for exact values.
⚠ Estimates modelled per component from molecular properties (chain length, cyclisation, oxidation- and deamidation-sensitive residues, light sensitivity). Indicative only — not lab-measured per batch.
Survodutide across EU suppliers
COA-verified EU vendors · Updated monthly